SUPERNUS PHARMACEUTICALS, INC.

For the period ended Dec 31, 2025. Filed Mar 2, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 2, 2026

SUPN$28.75+4.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Earnings (Loss)

(in thousands, except share and per share data)

	Year Ended December 31,
	2025	2024	2023
Revenues
Net product sales	$626,536	$637,696	$573,933
Collaboration revenue (ZURZUVAE)	52,996	—	—
Royalty, licensing, and other revenues	39,420	24,121	33,588
Total revenues	718,952	661,817	607,521
Costs and expenses
Cost of revenues(a)	74,562	77,906	83,779
Research and development	106,235	108,796	91,593
Selling, general and administrative	485,563	321,582	336,361
Amortization of intangible assets	89,456	77,977	82,385
Intangible asset impairment charges	—	—	20,189
Contingent consideration loss (gain)	25,419	(6,110)	(1,517)
Total costs and expenses	781,235	580,151	612,790
Operating earnings (loss)	(62,283)	81,666	(5,269)
Other income (expense)
Interest and other income, net	13,253	16,204	10,453
Interest expense	—	—	(2,415)
Total other income (expense), net	13,253	16,204	8,038
Earnings (loss) before income taxes	(49,030)	97,870	2,769
Income tax expense (benefit)	(10,480)	24,005	1,453
Net earnings (loss)	$(38,550)	$73,865	$1,316
Earnings (Loss) per share
Basic	$(0.68)	$1.34	$0.02
Diluted	$(0.68)	$1.32	$0.02
Weighted average shares outstanding
Basic	56,451,136	55,100,063	54,536,281
Diluted	56,451,136	55,958,537	55,506,828

(a) Excludes amortization of intangible assets.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.